{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:16:17Z","timestamp":1792444577013,"version":"4.5.0"},"reference-count":65,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The D816V-mutated variant of Kit triggers multiple signaling pathways and is considered essential for malignant transformation in mast cell (MC) neoplasms. We here describe that constitutive activation of the Stat5-PI3K-Akt-cascade controls neoplastic MC development. Retrovirally transduced active Stat5 (cS5F) was found to trigger PI3K and Akt activation, and to transform murine bone marrow progenitors into tissue-infiltrating MCs. Primary neoplastic Kit D816V+ MCs in patients with mastocytosis also displayed activated Stat5, which was found to localize to the cytoplasm and to form a signaling complex with PI3K, with consecutive Akt activation. Finally, the knock-down of either Stat5 or Akt activity resulted in growth inhibition of neoplastic Kit D816V+ MCs. These data suggest that a downstream Stat5-PI3K-Akt signaling cascade is essential for Kit D816V-mediated growth and survival of neoplastic MCs.<\/jats:p>","DOI":"10.1182\/blood-2007-09-115477","type":"journal-article","created":{"date-parts":[[2008,6,26]],"date-time":"2008-06-26T01:40:55Z","timestamp":1214444455000},"page":"2463-2473","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":105,"title":["Oncogenic Kit controls neoplastic mast cell growth through a Stat5\/PI3-kinase signaling cascade"],"prefix":"10.1182","volume":"112","author":[{"given":"Noria","family":"Harir","sequence":"first","affiliation":[{"name":"Inserm (EMI 351), Facult\u00e9 de M\u00e9decine, Universit\u00e9 de Picardie J. Verne, Amiens, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Boudot","sequence":"additional","affiliation":[{"name":"Inserm (EMI 351), Facult\u00e9 de M\u00e9decine, Universit\u00e9 de Picardie J. Verne, Amiens, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Friedbichler","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Sonneck","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudin","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Martin-Lanner\u00e9e","sequence":"additional","affiliation":[{"name":"Institut Cochin, Universit\u00e9 Paris Descartes, CNRS (UMR 8104), Paris, France;"},{"name":"Inserm U567, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Kenner","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria;"},{"name":"Department of Pathology, Medical University of Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Kerenyi","sequence":"additional","affiliation":[{"name":"Max F. Perutz Laboratories, Department of Medical Biochemistry, Division of Molecular Biology, Medical University of Vienna, Austria; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saliha","family":"Yahiaoui","sequence":"additional","affiliation":[{"name":"Inserm (EMI 351), Facult\u00e9 de M\u00e9decine, Universit\u00e9 de Picardie J. Verne, Amiens, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gouilleux-Gruart","sequence":"additional","affiliation":[{"name":"Inserm (EMI 351), Facult\u00e9 de M\u00e9decine, Universit\u00e9 de Picardie J. Verne, Amiens, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Gondry","sequence":"additional","affiliation":[{"name":"Centre Gyn\u00e9cologie-Obst\u00e9trique, Centre Hospitalier Universitaire, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"B\u00e9nit","sequence":"additional","affiliation":[{"name":"Institut Cochin, Universit\u00e9 Paris Descartes, CNRS (UMR 8104), Paris, France;"},{"name":"Inserm U567, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Dusanter-Fourt","sequence":"additional","affiliation":[{"name":"Institut Cochin, Universit\u00e9 Paris Descartes, CNRS (UMR 8104), Paris, France;"},{"name":"Inserm U567, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka\u00efss","family":"Lassoued","sequence":"additional","affiliation":[{"name":"Inserm (EMI 351), Facult\u00e9 de M\u00e9decine, Universit\u00e9 de Picardie J. Verne, Amiens, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Moriggl","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Gouilleux","sequence":"additional","affiliation":[{"name":"Inserm (EMI 351), Facult\u00e9 de M\u00e9decine, Universit\u00e9 de Picardie J. Verne, Amiens, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111713581263900_B1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0145-2126(01)00030-3","article-title":"Mast cell lineage development and phenotypic regulation.","volume":"25","author":"Austen","year":"2001","journal-title":"Leuk Res"},{"key":"2019111713581263900_B2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ni1158","article-title":"Mast cells in the development of adaptive immune responses.","volume":"6","author":"Galli","year":"2005","journal-title":"Nat Immunol"},{"key":"2019111713581263900_B3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal.","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"2019111713581263900_B4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","article-title":"Diagnosis and treatment of systemic mastocytosis: state of the art.","volume":"122","author":"Valent","year":"2003","journal-title":"Br J Haematol"},{"key":"2019111713581263900_B5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","article-title":"Systemic mastocytosis.","volume":"55","author":"Akin","year":"2004","journal-title":"Annu Rev Med"},{"key":"2019111713581263900_B6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria.","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"2019111713581263900_B7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/291159a0","article-title":"Spleen colony-forming cell as common precursor for tissue mast cells and granulocytes.","volume":"291","author":"Kitamura","year":"1981","journal-title":"Nature"},{"key":"2019111713581263900_B8","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.4049\/jimmunol.146.5.1410","article-title":"Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells.","volume":"146","author":"Kirshenbaum","year":"1991","journal-title":"J Immunol"},{"key":"2019111713581263900_B9","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.4049\/jimmunol.151.8.4221","article-title":"Monocytes do not make mast cells when cultured in the presence of SCF. Characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly\u2212, CD14\u2212, CD17\u2212, colony-forming cell.","volume":"151","author":"Agis","year":"1993","journal-title":"J Immunol"},{"key":"2019111713581263900_B10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1182\/blood.V52.2.447.bloodjournal522447","article-title":"Decrease of mast cells in W\/Wv mice and their increase by bone marrow transplantation.","volume":"52","author":"Kitamura","year":"1978","journal-title":"Blood"},{"key":"2019111713581263900_B11","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V53.3.492.492","article-title":"Decreased production of mast cells in S1\/S1d anemic mice.","volume":"53","author":"Kitamura","year":"1979","journal-title":"Blood"},{"key":"2019111713581263900_B12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0092-8674(88)90020-7","article-title":"The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene.","volume":"55","author":"Geissler","year":"1988","journal-title":"Cell"},{"key":"2019111713581263900_B13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0092-8674(90)90303-V","article-title":"The haematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus.","volume":"63","author":"Huang","year":"1990","journal-title":"Cell"},{"key":"2019111713581263900_B14","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111713581263900_B15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"key":"2019111713581263900_B16","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1084\/jem.20050807","article-title":"Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation.","volume":"202","author":"Zappulla","year":"2005","journal-title":"J Exp Med"},{"key":"2019111713581263900_B17","first-page":"357","article-title":"Stem cell factor activates STAT-5 DNA binding in IL-3-derived bone marrow mast cells.","volume":"25","author":"Ryan","year":"1997","journal-title":"Exp Hematol"},{"key":"2019111713581263900_B18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0889-8588(05)70294-X","article-title":"Kit signal transduction.","volume":"14","author":"Taylor","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"2019111713581263900_B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2005.08.055","article-title":"Signaling by Kit protein-tyrosine kinase: the stem cell factor receptor.","volume":"337","author":"Roskoski","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"2019111713581263900_B20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ni768","article-title":"Selective loss of gastrointestinal mast cells and impaired immunity in PI3K-deficient mice.","volume":"3","author":"Fukao","year":"2002","journal-title":"Nat Immunol"},{"key":"2019111713581263900_B21","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood.V99.5.1866","article-title":"Requirement of Gab2 for mast cell development and KitL\/ signaling.","volume":"99","author":"Nishida","year":"2002","journal-title":"Blood"},{"key":"2019111713581263900_B22","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2002-11-3490","article-title":"Stat5 expression is critical for mast cell development and survival.","volume":"102","author":"Shelburne","year":"2003","journal-title":"Blood"},{"key":"2019111713581263900_B23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/35084076","article-title":"Essential role for Gab2 in the allergic response.","volume":"412","author":"Gu","year":"2001","journal-title":"Nature"},{"key":"2019111713581263900_B24","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.4049\/jimmunol.177.5.3421","article-title":"Stat5 expression is required for IgE-mediated mast cell function.","volume":"177","author":"Barnstein","year":"2006","journal-title":"J Immunol"},{"key":"2019111713581263900_B25","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2002-04-1204","article-title":"Signal transducer and activator of transcription proteins in leukemias.","volume":"101","author":"Benekli","year":"2003","journal-title":"Blood"},{"key":"2019111713581263900_B26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-Kinase AKT pathway in human cancer.","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"2019111713581263900_B27","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1182\/blood.V95.6.2076","article-title":"Transforming properties of chimeric TEL-JAK proteins in Ba\/F3 cells.","volume":"95","author":"Lacronique","year":"2000","journal-title":"Blood"},{"key":"2019111713581263900_B28","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","article-title":"Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI3-K \/Akt-dependent pathway.","volume":"16","author":"Skorski","year":"1997","journal-title":"EMBO J"},{"key":"2019111713581263900_B29","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1084\/jem.183.3.811","article-title":"Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl.","volume":"183","author":"Carlesso","year":"1996","journal-title":"J Exp Med"},{"key":"2019111713581263900_B30","doi-asserted-by":"crossref","first-page":"32704","DOI":"10.1074\/jbc.M103100200","article-title":"TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3\u2032-kinase\/protein kinase B signaling pathway.","volume":"276","author":"Nguyen","year":"2001","journal-title":"J Biol Chem"},{"key":"2019111713581263900_B31","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V98.12.3390","article-title":"The TEL\/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways.","volume":"98","author":"Sternberg","year":"2001","journal-title":"Blood"},{"key":"2019111713581263900_B32","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood.V96.12.3907","article-title":"Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.","volume":"96","author":"Mizuki","year":"2000","journal-title":"Blood"},{"key":"2019111713581263900_B33","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutations of human c-KIT resistant to imatinib are sensitive to the tyrosine kinase inhibitor PKC412.","volume":"106","author":"Growney","year":"2005","journal-title":"Blood"},{"key":"2019111713581263900_B34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"2019111713581263900_B35","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.V98.5.1365","article-title":"Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V mutant.","volume":"98","author":"Chian","year":"2001","journal-title":"Blood"},{"key":"2019111713581263900_B36","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1097-2765(00)00067-8","article-title":"Stat5 is essential for the myelo- and lympho-proliferative disease induced by TEL\/JAK2.","volume":"6","author":"Schwaller","year":"2000","journal-title":"Mol Cell"},{"key":"2019111713581263900_B37","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/blood-2005-09-3596","article-title":"Clarifying the role of Stat5 in lymphoid development and Abelson induced transformation.","volume":"107","author":"Hoelbl","year":"2006","journal-title":"Blood"},{"key":"2019111713581263900_B38","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1182\/blood-2005-10-4110","article-title":"STAT5 signaling is required for the efficient induction and maintenance of CML in mice.","volume":"107","author":"Ye","year":"2006","journal-title":"Blood"},{"key":"2019111713581263900_B39","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","article-title":"Role for Gab2 in transformation by BCR\/ABL.","volume":"1","author":"Sattler","year":"2002","journal-title":"Cancer Cell"},{"key":"2019111713581263900_B40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ccr.2004.12.010","article-title":"Stat5 tetramer association is associated with leukemogenesis.","volume":"7","author":"Moriggl","year":"2005","journal-title":"Cancer Cell"},{"key":"2019111713581263900_B41","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1042\/BJ20041523","article-title":"Activated STAT5 proteins induce activation of the PI 3-kinase\/Akt and Ras\/MAPK pathways via the Gab2 scaffolding adapter.","volume":"390","author":"Nyga","year":"2005","journal-title":"Biochem J"},{"key":"2019111713581263900_B42","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1182\/blood-2006-01-029918","article-title":"Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias.","volume":"109","author":"Harir","year":"2007","journal-title":"Blood"},{"key":"2019111713581263900_B43","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0145-2126(88)90050-1","article-title":"Establishment of an immature mast cell line from a patient with mast cell leukemia.","volume":"12","author":"Butterfield","year":"1988","journal-title":"Leukemia Res"},{"key":"2019111713581263900_B44","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1006\/mthe.2001.0282","article-title":"Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD\/SCID mouse repopulating cells, after transduction with modified trip lentiviral vectors.","volume":"4","author":"Sirven","year":"2001","journal-title":"Mol Ther"},{"key":"2019111713581263900_B45","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/29.4.6166661","article-title":"Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.","volume":"29","author":"Hsu","year":"1981","journal-title":"J Histochem Cytochem"},{"key":"2019111713581263900_B46","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1053\/hupa.2001.24319","article-title":"Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117\/Kit, and bcl-x(L).","volume":"32","author":"Jordan","year":"2001","journal-title":"Hum Pathol"},{"key":"2019111713581263900_B47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2141.2007.06708.x","article-title":"Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation.","volume":"139","author":"Zuluaga Toro","year":"2007","journal-title":"Br J Haematol"},{"key":"2019111713581263900_B48","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0952-7915(99)80010-7","article-title":"Mast cells as sentinels of innate immunity.","volume":"11","author":"Galli","year":"1999","journal-title":"Curr Opin Immunol"},{"key":"2019111713581263900_B49","first-page":"3775","article-title":"IL-3-dependent murine mast cells undergo apoptosis on removal of IL-3: prevention of apoptosis by c-kit ligand.","volume":"151","author":"Mekori","year":"1993","journal-title":"J lmmunol"},{"key":"2019111713581263900_B50","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/blood-2004-07-2639","article-title":"Rapid and large amount of autocrine IL-3 production is responsible for mast cell survival by IgE in the absence of antigen.","volume":"105","author":"Kohno","year":"2005","journal-title":"Blood"},{"key":"2019111713581263900_B51","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0145-2126(01)00046-7","article-title":"Mastocytosis: molecular mechanisms and clinical disease heterogeneity.","volume":"25","author":"Metcalfe","year":"2001","journal-title":"Leukemia Res"},{"key":"2019111713581263900_B52","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood.V80.9.2237.2237","article-title":"Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor\/kit-ligand in long-term culture.","volume":"80","author":"Valent","year":"1992","journal-title":"Blood"},{"key":"2019111713581263900_B53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000085431","article-title":"Stat5a is essential for the proliferation and survival of murine mast cells.","volume":"137","author":"Ikeda","year":"2005","journal-title":"Int Arch Allergy Immunol"},{"key":"2019111713581263900_B54","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00109-003-0475-2","article-title":"Role of phosphoinositide 3-kinase signaling in mast cells: new insights from knockout mouse studies.","volume":"81","author":"Fukao","year":"2003","journal-title":"J Mol Med"},{"key":"2019111713581263900_B55","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/blood-2007-05-090969","article-title":"Cytoplasmic localization of phosphorylated STAT5 in human acute myeloid leukemia is inversely correlated with Flt3-ITD.","volume":"110","author":"Bunting","year":"2007","journal-title":"Blood"},{"key":"2019111713581263900_B56","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood.V94.7.2333.419k30_2333_2342","article-title":"Demonstration that human mast cells arise from a progenitor cell population that is CD34+, c-kit+, and expresses aminopeptidase N(CD13).","volume":"94","author":"Kirshenbaum","year":"1999","journal-title":"Blood"},{"key":"2019111713581263900_B57","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood.V99.2.479","article-title":"Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5.","volume":"99","author":"Bunting","year":"2002","journal-title":"Blood"},{"key":"2019111713581263900_B58","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1084\/jem.20041024","article-title":"Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation","volume":"200","author":"Schuringa","year":"2004","journal-title":"J Exp Med"},{"key":"2019111713581263900_B59","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1084\/jem.20042541","article-title":"Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis.","volume":"202","author":"Kato","year":"2005","journal-title":"J Exp Med"},{"key":"2019111713581263900_B60","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"2019111713581263900_B61","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.onc.1206120","article-title":"Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.","volume":"22","author":"Zermati","year":"2003","journal-title":"Oncogene"},{"key":"2019111713581263900_B62","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"2019111713581263900_B63","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"2019111713581263900_B64","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood"},{"key":"2019111713581263900_B65","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00062752-200207000-00007","article-title":"Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia.","volume":"9","author":"Gorre","year":"2002","journal-title":"Curr Opin Hematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/6\/2463\/1484750\/zh801808002463.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/6\/2463\/1484750\/zh801808002463.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:50Z","timestamp":1684454450000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/112\/6\/2463\/24919\/Oncogenic-Kit-controls-neoplastic-mast-cell-growth"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,15]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,9,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-09-115477","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,15]]}}}